• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Botox, Juvederm sales lift Allergan in first quarter

Quote

anonymous

Guest
Allergan plc reported a 3% improvement in revenues to $3.7 billion for the first quarter of 2018 compared to the prior year period, driven by a 13% increase in its core business which includes the Botox and Juvederm brands.
Net loss for the quarter was $332.5 million or $0.99 per diluted share compared to $2.6 billion or $7.86 per diluted share for the same period last year. Adjusted EPS totaled $3.74.
US Specialized Therapeutics revenues grew 6.5% while U.S. General Medicine fell 9.1% compared to the prior year period. International revenues rose 9%.
Full article: https://news.alphastreet.com/allergan-1q-2018-results/
 




anonymous said:
Allergan plc reported a 3% improvement in revenues to $3.7 billion for the first quarter of 2018 compared to the prior year period, driven by a 13% increase in its core business which includes the Botox and Juvederm brands.
Net loss for the quarter was $332.5 million or $0.99 per diluted share compared to $2.6 billion or $7.86 per diluted share for the same period last year. Adjusted EPS totaled $3.74.
US Specialized Therapeutics revenues grew 6.5% while U.S. General Medicine fell 9.1% compared to the prior year period. International revenues rose 9%.
Full article: https://news.alphastreet.com/allergan-1q-2018-results/
Click to expand...

Which Allergan brands are the lowest performing?
 








The street wanted a solid strategic direction with an off loading of WH or other. Not dialogue about more worthless share buy backs etc. AGN will begin losing institutional investors and this stock price will tank even more because of it. Since late July 2015, Saunders has been able to lose over 50% of the stock price with his shoot by the hip idea of how to grow AGN. The street is tired of it.
 




Great q1 report, then we get hit with the news we $700 million for a stinking pile of trash that will yield zero products. Then Brent goes dishrag on the call and provides limp wristed no- leadership babble... this stock is going to freefall
 
















Hmmm and then you don’t pay the
Salesforce that performs??? What a joke - 30 plus turnover Facial reps recently . . . Better places to be that appreciate their managers.
 




anonymous said:
The street remains unimpressed.

I've also seen this train wreck from the inside and I'm glad I'm out.
Click to expand...

It's bad. People with half a brain are gone. Loyalists hanging on to the last railing on the deck of the Titanic are the ones left. Sad to see. Once a GREAT company, not a good company, a great one. Sad.
 




Top Bottom
Back
Quote